Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients.
Int J Mol Sci. 2024 Feb 20;25(5):2490. doi: 10.3390/ijms25052490.
Int J Mol Sci. 2024.
PMID: 38473737
Free PMC article.
Dissecting Immunotherapy Strategies for Small Cell Lung Cancer: Antibodies, Ionizing Radiation and CAR-T.
Guaitoli G, Neri G, Cabitza E, Natalizio S, Mastrodomenico L, Talerico S, Trudu L, Lauro C, Chiavelli C, Baschieri MC, Bruni A, Dominici M, Bertolini F.
Guaitoli G, et al. Among authors: natalizio s.
Int J Mol Sci. 2022 Oct 22;23(21):12728. doi: 10.3390/ijms232112728.
Int J Mol Sci. 2022.
PMID: 36361523
Free PMC article.
Review.
Item in Clipboard
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib.
Del Re M, Crucitta S, Omarini C, Bargagna I, Mongillo M, Palleschi M, Stucci S, Meattini I, D'Onofrio R, Lorenzini G, Biondani P, De Giorgi U, Porta C, Livi L, Natalizio S, Fontana A, Giontella E, Angelini L, Fogli S, Danesi R.
Del Re M, et al. Among authors: natalizio s.
Breast. 2022 Dec;66:157-161. doi: 10.1016/j.breast.2022.10.005. Epub 2022 Oct 15.
Breast. 2022.
PMID: 36283134
Free PMC article.
Item in Clipboard
Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: a single institutional retrospective report.
Trudu L, Guaitoli G, Bertolini F, Maur M, Santini C, Papapietro VR, Talerico S, Natalizio S, Isca C, Dominici M, Barbieri F.
Trudu L, et al. Among authors: natalizio s.
Immunotherapy. 2022 Apr 13. doi: 10.2217/imt-2021-0165. Online ahead of print.
Immunotherapy. 2022.
PMID: 35416048
Item in Clipboard
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A, Cannita K, Tiseo M, Cortinovis DL, Aerts JGJV, Baldessari C, Giusti R, Ferrara MG, D'Argento E, Grossi F, Guida A, Berardi R, Morabito A, Genova C, Antonuzzo L, Mazzoni F, De Toma A, Signorelli D, Gelibter A, Targato G, Rastelli F, Chiari R, Rocco D, Gori S, De Tursi M, Mansueto G, Zoratto F, Filetti M, Bracarda S, Citarella F, Russano M, Cantini L, Nigro O, Buti S, Minuti G, Landi L, Ricciardi S, Migliorino MR, Natalizio S, Simona C, De Filippis M, Metro G, Adamo V, Russo A, Spinelli GP, Di Maio M, Banna GL, Friedlaender A, Addeo A, Pinato DJ, Ficorella C, Porzio G.
Cortellini A, et al. Among authors: natalizio s.
Eur J Cancer. 2021 May;148:24-35. doi: 10.1016/j.ejca.2021.02.005. Epub 2021 Mar 12.
Eur J Cancer. 2021.
PMID: 33721704
Free article.
Item in Clipboard
Cite
Cite